EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

To be considered for this study, you must be over 18 years old and have a confirmed diagnosis of tubo-ovarian or uterine carcinosarcoma. The cancer must have come back or grown after you've already had at least one, but no more than two, rounds of chemotherapy. Doctors will also need to see that at least 5% of your tumour is made up of the sarcoma type of cancer cells.

It's important that your general health is good enough to take part in a study like this. This includes having good organ function (like your kidneys and liver) and being able to manage your daily activities without too much difficulty. You'll need to undergo scans like PET, CT, or MRI to confirm the cancer's return and show there are areas that can be measured to track treatment progress.

Finally, you must be willing and able to understand and sign a consent form, and commit to attending all study appointments and following the treatment plan for the duration of the trial.

If you decide to take part in this study, you'll first have some tests to make sure you're suitable, including blood tests and scans. Once accepted, you'll receive either eribulin as a single drug, or eribulin combined with pembrolizumab. These medications are given as infusions, usually in a hospital or clinic setting.

You'll have regular appointments, including physical exams, blood tests, and scans, to monitor your health, how you're responding to treatment, and to check for any side effects. The exact number of visits and the full treatment duration will be explained by the study team, but typically, clinical trials involve consistent monitoring over several months, sometimes with follow-up appointments extending beyond active treatment. You'll be told about the total estimated time commitment if you join.